CD274 and neoplasm: The immunohistochemical analysis revealed a PD-L1 tumor proportion score (TPS) of more than 50%, and the genetic analysis with next-generation sequencing (NGS) of EGFR, KRAS, BRAF, LKB1, ERBB2 and MET did not reveal any targetable mutations.